Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Income Statement
Earnings Waterfall
Shenzhen New Industries Biomedical Engineering Co Ltd
Revenue
|
3.9B
CNY
|
Cost of Revenue
|
-1.1B
CNY
|
Gross Profit
|
2.9B
CNY
|
Operating Expenses
|
-1.1B
CNY
|
Operating Income
|
1.8B
CNY
|
Other Expenses
|
-130.9m
CNY
|
Net Income
|
1.7B
CNY
|
Income Statement
Shenzhen New Industries Biomedical Engineering Co Ltd
Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||
Revenue |
1 570
N/A
|
2 195
+40%
|
2 439
+11%
|
2 451
+0%
|
2 519
+3%
|
2 545
+1%
|
2 756
+8%
|
2 737
-1%
|
2 948
+8%
|
3 047
+3%
|
3 180
+4%
|
3 495
+10%
|
3 658
+5%
|
3 930
+7%
|
|
Gross Profit | |||||||||||||||
Cost of Revenue |
(350)
|
(501)
|
(578)
|
(669)
|
(729)
|
(734)
|
(798)
|
(825)
|
(883)
|
(906)
|
(986)
|
(1 016)
|
(1 023)
|
(1 062)
|
|
Gross Profit |
1 220
N/A
|
1 694
+39%
|
1 860
+10%
|
1 781
-4%
|
1 789
+0%
|
1 811
+1%
|
1 957
+8%
|
1 911
-2%
|
2 065
+8%
|
2 141
+4%
|
2 194
+2%
|
2 479
+13%
|
2 635
+6%
|
2 867
+9%
|
|
Operating Income | |||||||||||||||
Operating Expenses |
(445)
|
(656)
|
(717)
|
(753)
|
(766)
|
(718)
|
(696)
|
(724)
|
(774)
|
(779)
|
(804)
|
(911)
|
(943)
|
(1 083)
|
|
Selling, General & Administrative |
(365)
|
(483)
|
(597)
|
(634)
|
(623)
|
(493)
|
(505)
|
(495)
|
(507)
|
(433)
|
(490)
|
(583)
|
(609)
|
(686)
|
|
Research & Development |
(114)
|
(136)
|
(163)
|
(155)
|
(180)
|
(198)
|
(233)
|
(262)
|
(296)
|
(297)
|
(342)
|
(357)
|
(366)
|
(336)
|
|
Depreciation & Amortization |
0
|
(51)
|
0
|
0
|
0
|
(64)
|
0
|
0
|
0
|
(79)
|
0
|
0
|
0
|
(108)
|
|
Other Operating Expenses |
34
|
14
|
44
|
37
|
36
|
37
|
42
|
34
|
29
|
29
|
28
|
29
|
31
|
47
|
|
Operating Income |
775
N/A
|
1 038
+34%
|
1 143
+10%
|
1 029
-10%
|
1 023
-1%
|
1 093
+7%
|
1 261
+15%
|
1 187
-6%
|
1 291
+9%
|
1 362
+5%
|
1 390
+2%
|
1 569
+13%
|
1 692
+8%
|
1 785
+5%
|
|
Pre-Tax Income | |||||||||||||||
Interest Income Expense |
37
|
61
|
31
|
12
|
34
|
44
|
32
|
107
|
135
|
141
|
161
|
147
|
118
|
111
|
|
Non-Reccuring Items |
0
|
(1)
|
0
|
0
|
0
|
(2)
|
0
|
1
|
1
|
(1)
|
0
|
0
|
0
|
(1)
|
|
Total Other Income |
(1)
|
(1)
|
(2)
|
(4)
|
(3)
|
(0)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(1)
|
|
Pre-Tax Income |
812
N/A
|
1 097
+35%
|
1 173
+7%
|
1 037
-12%
|
1 055
+2%
|
1 136
+8%
|
1 290
+14%
|
1 295
+0%
|
1 426
+10%
|
1 501
+5%
|
1 549
+3%
|
1 713
+11%
|
1 807
+6%
|
1 893
+5%
|
|
Net Income | |||||||||||||||
Tax Provision |
(113)
|
(158)
|
(177)
|
(145)
|
(148)
|
(162)
|
(176)
|
(180)
|
(193)
|
(173)
|
(174)
|
(204)
|
(217)
|
(239)
|
|
Income from Continuing Operations |
698
|
939
|
997
|
892
|
906
|
974
|
1 114
|
1 115
|
1 233
|
1 328
|
1 375
|
1 508
|
1 590
|
1 654
|
|
Net Income (Common) |
698
N/A
|
939
+34%
|
997
+6%
|
892
-10%
|
906
+2%
|
974
+7%
|
1 114
+14%
|
1 115
+0%
|
1 233
+11%
|
1 328
+8%
|
1 375
+4%
|
1 508
+10%
|
1 590
+5%
|
1 654
+4%
|
|
EPS (Diluted) |
0.9
N/A
|
1.25
+39%
|
1.26
+1%
|
1.13
-10%
|
1.15
+2%
|
1.24
+8%
|
1.41
+14%
|
1.42
+1%
|
1.57
+11%
|
1.69
+8%
|
1.75
+4%
|
1.92
+10%
|
2.02
+5%
|
2.1
+4%
|